nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—DDC—nephron tubule—kidney cancer	0.0118	0.0996	CbGeAlD
Methyldopa—DDC—renal system—kidney cancer	0.0108	0.0905	CbGeAlD
Methyldopa—DDC—kidney—kidney cancer	0.0104	0.0875	CbGeAlD
Methyldopa—DDC—cortex of kidney—kidney cancer	0.0101	0.0852	CbGeAlD
Methyldopa—SLC15A1—nephron tubule—kidney cancer	0.0088	0.074	CbGeAlD
Methyldopa—SLC15A1—renal system—kidney cancer	0.008	0.0673	CbGeAlD
Methyldopa—COMT—nephron tubule—kidney cancer	0.00782	0.0659	CbGeAlD
Methyldopa—SLC15A1—kidney—kidney cancer	0.00773	0.0651	CbGeAlD
Methyldopa—COMT—renal system—kidney cancer	0.00711	0.0599	CbGeAlD
Methyldopa—COMT—kidney—kidney cancer	0.00688	0.0579	CbGeAlD
Methyldopa—COMT—cortex of kidney—kidney cancer	0.0067	0.0564	CbGeAlD
Methyldopa—COMT—gonad—kidney cancer	0.00638	0.0537	CbGeAlD
Methyldopa—COMT—cardiac atrium—kidney cancer	0.00637	0.0536	CbGeAlD
Methyldopa—Isoprenaline—MAPK1—kidney cancer	0.00599	0.41	CrCbGaD
Methyldopa—ADRA2A—cortex of kidney—kidney cancer	0.00341	0.0287	CbGeAlD
Methyldopa—ADRA2A—gonad—kidney cancer	0.00325	0.0273	CbGeAlD
Methyldopa—ADRA2A—cardiac atrium—kidney cancer	0.00324	0.0273	CbGeAlD
Methyldopa—Aminosalicylic Acid—PTGS1—kidney cancer	0.00262	0.179	CrCbGaD
Methyldopa—Mesalazine—PTGS1—kidney cancer	0.00205	0.14	CrCbGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—HSPD1—kidney cancer	0.00166	0.00945	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—HNF1B—kidney cancer	0.00155	0.00883	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—KCNMA1—kidney cancer	0.00151	0.0086	CbGpPWpGaD
Methyldopa—Aminosalicylic Acid—PTGS2—kidney cancer	0.0015	0.102	CrCbGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—IL13—kidney cancer	0.00139	0.00794	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—JUND—kidney cancer	0.00135	0.00772	CbGpPWpGaD
Methyldopa—COMT—Phase II conjugation—GSTP1—kidney cancer	0.00133	0.00758	CbGpPWpGaD
Methyldopa—Isoprenaline—CYP1A1—kidney cancer	0.00129	0.0881	CrCbGaD
Methyldopa—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—kidney cancer	0.00126	0.0072	CbGpPWpGaD
Methyldopa—COMT—Phase II conjugation—GSTM1—kidney cancer	0.00122	0.00697	CbGpPWpGaD
Methyldopa—Nervous system disorder—Sorafenib—kidney cancer	0.00118	0.00171	CcSEcCtD
Methyldopa—Mediastinal disorder—Gemcitabine—kidney cancer	0.00118	0.0017	CcSEcCtD
Methyldopa—Thrombocytopenia—Sorafenib—kidney cancer	0.00118	0.0017	CcSEcCtD
Methyldopa—Rash—Temsirolimus—kidney cancer	0.00117	0.0017	CcSEcCtD
Methyldopa—Mesalazine—PTGS2—kidney cancer	0.00117	0.0803	CrCbGaD
Methyldopa—Dermatitis—Temsirolimus—kidney cancer	0.00117	0.0017	CcSEcCtD
Methyldopa—Breast disorder—Capecitabine—kidney cancer	0.00117	0.0017	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Capecitabine—kidney cancer	0.00117	0.00169	CcSEcCtD
Methyldopa—Skin disorder—Sorafenib—kidney cancer	0.00117	0.00169	CcSEcCtD
Methyldopa—Headache—Temsirolimus—kidney cancer	0.00117	0.00169	CcSEcCtD
Methyldopa—Dizziness—Pazopanib—kidney cancer	0.00116	0.00168	CcSEcCtD
Methyldopa—Oedema—Sunitinib—kidney cancer	0.00116	0.00167	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Erlotinib—kidney cancer	0.00115	0.00167	CcSEcCtD
Methyldopa—Hepatobiliary disease—Paclitaxel—kidney cancer	0.00115	0.00167	CcSEcCtD
Methyldopa—Hepatocellular injury—Doxorubicin—kidney cancer	0.00115	0.00167	CcSEcCtD
Methyldopa—Infection—Sunitinib—kidney cancer	0.00115	0.00166	CcSEcCtD
Methyldopa—Constipation—Erlotinib—kidney cancer	0.00114	0.00165	CcSEcCtD
Methyldopa—Myalgia—Dactinomycin—kidney cancer	0.00114	0.00165	CcSEcCtD
Methyldopa—Nervous system disorder—Sunitinib—kidney cancer	0.00113	0.00164	CcSEcCtD
Methyldopa—Thrombocytopenia—Sunitinib—kidney cancer	0.00113	0.00164	CcSEcCtD
Methyldopa—Abdominal distension—Capecitabine—kidney cancer	0.00113	0.00163	CcSEcCtD
Methyldopa—Skin disorder—Sunitinib—kidney cancer	0.00112	0.00163	CcSEcCtD
Methyldopa—COMT—Biological oxidations—GSTT1—kidney cancer	0.00112	0.0064	CbGpPWpGaD
Methyldopa—Vomiting—Pazopanib—kidney cancer	0.00112	0.00161	CcSEcCtD
Methyldopa—Bradycardia—Paclitaxel—kidney cancer	0.00111	0.00161	CcSEcCtD
Methyldopa—Colitis—Doxorubicin—kidney cancer	0.00111	0.0016	CcSEcCtD
Methyldopa—Rash—Pazopanib—kidney cancer	0.00111	0.0016	CcSEcCtD
Methyldopa—Nausea—Temsirolimus—kidney cancer	0.00111	0.0016	CcSEcCtD
Methyldopa—Dermatitis—Pazopanib—kidney cancer	0.00111	0.0016	CcSEcCtD
Methyldopa—Headache—Pazopanib—kidney cancer	0.0011	0.00159	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.0011	0.00159	CcSEcCtD
Methyldopa—Oedema—Dactinomycin—kidney cancer	0.0011	0.00158	CcSEcCtD
Methyldopa—Body temperature increased—Everolimus—kidney cancer	0.0011	0.00158	CcSEcCtD
Methyldopa—Angina pectoris—Capecitabine—kidney cancer	0.00109	0.00158	CcSEcCtD
Methyldopa—Infection—Dactinomycin—kidney cancer	0.00109	0.00157	CcSEcCtD
Methyldopa—DDC—Amino acid and derivative metabolism—PSMD7—kidney cancer	0.00108	0.00617	CbGpPWpGaD
Methyldopa—Connective tissue disorder—Paclitaxel—kidney cancer	0.00108	0.00156	CcSEcCtD
Methyldopa—Leukopenia—Vincristine—kidney cancer	0.00107	0.00155	CcSEcCtD
Methyldopa—Thrombocytopenia—Dactinomycin—kidney cancer	0.00107	0.00155	CcSEcCtD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.00107	0.0061	CbGpPWpGaD
Methyldopa—Pancytopenia—Capecitabine—kidney cancer	0.00107	0.00154	CcSEcCtD
Methyldopa—Body temperature increased—Erlotinib—kidney cancer	0.00106	0.00153	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—EGR1—kidney cancer	0.00106	0.00602	CbGpPWpGaD
Methyldopa—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.00105	0.00153	CcSEcCtD
Methyldopa—COMT—Biological oxidations—PTGS1—kidney cancer	0.00105	0.006	CbGpPWpGaD
Methyldopa—Nausea—Pazopanib—kidney cancer	0.00104	0.00151	CcSEcCtD
Methyldopa—Paraesthesia—Sunitinib—kidney cancer	0.00104	0.0015	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Sorafenib—kidney cancer	0.00104	0.0015	CcSEcCtD
Methyldopa—COMT—Neuronal System—KCNMA1—kidney cancer	0.00103	0.00588	CbGpPWpGaD
Methyldopa—Constipation—Sorafenib—kidney cancer	0.00103	0.00149	CcSEcCtD
Methyldopa—Hypersensitivity—Vinblastine—kidney cancer	0.00102	0.00148	CcSEcCtD
Methyldopa—Myalgia—Vincristine—kidney cancer	0.00102	0.00148	CcSEcCtD
Methyldopa—Weight increased—Capecitabine—kidney cancer	0.00102	0.00148	CcSEcCtD
Methyldopa—Hypersensitivity—Everolimus—kidney cancer	0.00102	0.00148	CcSEcCtD
Methyldopa—Leukopenia—Gemcitabine—kidney cancer	0.00102	0.00147	CcSEcCtD
Methyldopa—Cardiac disorder—Paclitaxel—kidney cancer	0.00102	0.00147	CcSEcCtD
Methyldopa—DDC—Amino acid and derivative metabolism—SLC5A5—kidney cancer	0.00101	0.00578	CbGpPWpGaD
Methyldopa—Infestation—Capecitabine—kidney cancer	0.001	0.00145	CcSEcCtD
Methyldopa—Infestation NOS—Capecitabine—kidney cancer	0.001	0.00145	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000999	0.00145	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000998	0.00144	CcSEcCtD
Methyldopa—Asthenia—Vinblastine—kidney cancer	0.000998	0.00144	CcSEcCtD
Methyldopa—COMT—Transmission across Chemical Synapses—ACHE—kidney cancer	0.000995	0.00567	CbGpPWpGaD
Methyldopa—Asthenia—Everolimus—kidney cancer	0.000994	0.00144	CcSEcCtD
Methyldopa—Angiopathy—Paclitaxel—kidney cancer	0.000993	0.00144	CcSEcCtD
Methyldopa—Constipation—Sunitinib—kidney cancer	0.00099	0.00143	CcSEcCtD
Methyldopa—Mediastinal disorder—Paclitaxel—kidney cancer	0.000986	0.00143	CcSEcCtD
Methyldopa—Oedema—Vincristine—kidney cancer	0.000979	0.00142	CcSEcCtD
Methyldopa—Jaundice—Capecitabine—kidney cancer	0.000975	0.00141	CcSEcCtD
Methyldopa—Infection—Vincristine—kidney cancer	0.000972	0.00141	CcSEcCtD
Methyldopa—Arthralgia—Gemcitabine—kidney cancer	0.000969	0.0014	CcSEcCtD
Methyldopa—Myalgia—Gemcitabine—kidney cancer	0.000969	0.0014	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000962	0.00139	CcSEcCtD
Methyldopa—Nervous system disorder—Vincristine—kidney cancer	0.00096	0.00139	CcSEcCtD
Methyldopa—Asthenia—Erlotinib—kidney cancer	0.000959	0.00139	CcSEcCtD
Methyldopa—Mental disorder—Paclitaxel—kidney cancer	0.000959	0.00139	CcSEcCtD
Methyldopa—Thrombocytopenia—Vincristine—kidney cancer	0.000958	0.00139	CcSEcCtD
Methyldopa—Diarrhoea—Vinblastine—kidney cancer	0.000952	0.00138	CcSEcCtD
Methyldopa—Body temperature increased—Sorafenib—kidney cancer	0.000951	0.00138	CcSEcCtD
Methyldopa—Diarrhoea—Everolimus—kidney cancer	0.000948	0.00137	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000947	0.0054	CbGpPWpGaD
Methyldopa—Hepatobiliary disease—Capecitabine—kidney cancer	0.000946	0.00137	CcSEcCtD
Methyldopa—Flatulence—Paclitaxel—kidney cancer	0.000939	0.00136	CcSEcCtD
Methyldopa—Agranulocytosis—Capecitabine—kidney cancer	0.000933	0.00135	CcSEcCtD
Methyldopa—Eczema—Doxorubicin—kidney cancer	0.000931	0.00135	CcSEcCtD
Methyldopa—ADRA2A—Regulation of insulin secretion—ITPR2—kidney cancer	0.000931	0.00531	CbGpPWpGaD
Methyldopa—Oedema—Gemcitabine—kidney cancer	0.000928	0.00134	CcSEcCtD
Methyldopa—Cardiac failure congestive—Doxorubicin—kidney cancer	0.000923	0.00133	CcSEcCtD
Methyldopa—Infection—Gemcitabine—kidney cancer	0.000922	0.00133	CcSEcCtD
Methyldopa—Dizziness—Vinblastine—kidney cancer	0.00092	0.00133	CcSEcCtD
Methyldopa—Dizziness—Everolimus—kidney cancer	0.000916	0.00133	CcSEcCtD
Methyldopa—Body temperature increased—Sunitinib—kidney cancer	0.000915	0.00132	CcSEcCtD
Methyldopa—Diarrhoea—Erlotinib—kidney cancer	0.000915	0.00132	CcSEcCtD
Methyldopa—Bradycardia—Capecitabine—kidney cancer	0.000914	0.00132	CcSEcCtD
Methyldopa—Nervous system disorder—Gemcitabine—kidney cancer	0.000911	0.00132	CcSEcCtD
Methyldopa—Thrombocytopenia—Gemcitabine—kidney cancer	0.000909	0.00132	CcSEcCtD
Methyldopa—Skin disorder—Gemcitabine—kidney cancer	0.000902	0.0013	CcSEcCtD
Methyldopa—Hepatitis—Capecitabine—kidney cancer	0.000898	0.0013	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000892	0.00129	CcSEcCtD
Methyldopa—Hypersensitivity—Sorafenib—kidney cancer	0.000886	0.00128	CcSEcCtD
Methyldopa—Vomiting—Vinblastine—kidney cancer	0.000884	0.00128	CcSEcCtD
Methyldopa—Dizziness—Erlotinib—kidney cancer	0.000884	0.00128	CcSEcCtD
Methyldopa—Connective tissue disorder—Capecitabine—kidney cancer	0.000882	0.00128	CcSEcCtD
Methyldopa—Vomiting—Everolimus—kidney cancer	0.000881	0.00127	CcSEcCtD
Methyldopa—Paraesthesia—Vincristine—kidney cancer	0.000879	0.00127	CcSEcCtD
Methyldopa—Rash—Everolimus—kidney cancer	0.000874	0.00126	CcSEcCtD
Methyldopa—Dermatitis—Everolimus—kidney cancer	0.000873	0.00126	CcSEcCtD
Methyldopa—Headache—Vinblastine—kidney cancer	0.000871	0.00126	CcSEcCtD
Methyldopa—Headache—Everolimus—kidney cancer	0.000868	0.00126	CcSEcCtD
Methyldopa—COMT—Transmission across Chemical Synapses—BCHE—kidney cancer	0.000867	0.00494	CbGpPWpGaD
Methyldopa—Body temperature increased—Dactinomycin—kidney cancer	0.000866	0.00125	CcSEcCtD
Methyldopa—Asthenia—Sorafenib—kidney cancer	0.000863	0.00125	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—EGR1—kidney cancer	0.000862	0.00491	CbGpPWpGaD
Methyldopa—Leukopenia—Paclitaxel—kidney cancer	0.000853	0.00123	CcSEcCtD
Methyldopa—Hypersensitivity—Sunitinib—kidney cancer	0.000853	0.00123	CcSEcCtD
Methyldopa—Vomiting—Erlotinib—kidney cancer	0.00085	0.00123	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000846	0.00122	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Vincristine—kidney cancer	0.000845	0.00122	CcSEcCtD
Methyldopa—Rash—Erlotinib—kidney cancer	0.000843	0.00122	CcSEcCtD
Methyldopa—Dermatitis—Erlotinib—kidney cancer	0.000842	0.00122	CcSEcCtD
Methyldopa—Headache—Erlotinib—kidney cancer	0.000837	0.00121	CcSEcCtD
Methyldopa—Constipation—Vincristine—kidney cancer	0.000837	0.00121	CcSEcCtD
Methyldopa—Paraesthesia—Gemcitabine—kidney cancer	0.000834	0.00121	CcSEcCtD
Methyldopa—Cardiac disorder—Capecitabine—kidney cancer	0.000833	0.00121	CcSEcCtD
Methyldopa—Asthenia—Sunitinib—kidney cancer	0.00083	0.0012	CcSEcCtD
Methyldopa—Nausea—Vinblastine—kidney cancer	0.000826	0.0012	CcSEcCtD
Methyldopa—Nausea—Everolimus—kidney cancer	0.000823	0.00119	CcSEcCtD
Methyldopa—Diarrhoea—Sorafenib—kidney cancer	0.000823	0.00119	CcSEcCtD
Methyldopa—Angiopathy—Capecitabine—kidney cancer	0.000815	0.00118	CcSEcCtD
Methyldopa—Myalgia—Paclitaxel—kidney cancer	0.000811	0.00117	CcSEcCtD
Methyldopa—Arthralgia—Paclitaxel—kidney cancer	0.000811	0.00117	CcSEcCtD
Methyldopa—Mediastinal disorder—Capecitabine—kidney cancer	0.000809	0.00117	CcSEcCtD
Methyldopa—Hypersensitivity—Dactinomycin—kidney cancer	0.000807	0.00117	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000805	0.00117	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000802	0.00116	CcSEcCtD
Methyldopa—Dizziness—Sorafenib—kidney cancer	0.000795	0.00115	CcSEcCtD
Methyldopa—Constipation—Gemcitabine—kidney cancer	0.000794	0.00115	CcSEcCtD
Methyldopa—Nausea—Erlotinib—kidney cancer	0.000794	0.00115	CcSEcCtD
Methyldopa—Diarrhoea—Sunitinib—kidney cancer	0.000792	0.00115	CcSEcCtD
Methyldopa—Mental disorder—Capecitabine—kidney cancer	0.000787	0.00114	CcSEcCtD
Methyldopa—Asthenia—Dactinomycin—kidney cancer	0.000786	0.00114	CcSEcCtD
Methyldopa—COMT—Biological oxidations—GSTP1—kidney cancer	0.000778	0.00444	CbGpPWpGaD
Methyldopa—Oedema—Paclitaxel—kidney cancer	0.000777	0.00112	CcSEcCtD
Methyldopa—Body temperature increased—Vincristine—kidney cancer	0.000774	0.00112	CcSEcCtD
Methyldopa—Liver function test abnormal—Doxorubicin—kidney cancer	0.000772	0.00112	CcSEcCtD
Methyldopa—Infection—Paclitaxel—kidney cancer	0.000772	0.00112	CcSEcCtD
Methyldopa—Flatulence—Capecitabine—kidney cancer	0.00077	0.00111	CcSEcCtD
Methyldopa—COMT—Metapathway biotransformation—GSTP1—kidney cancer	0.000768	0.00438	CbGpPWpGaD
Methyldopa—Dizziness—Sunitinib—kidney cancer	0.000765	0.00111	CcSEcCtD
Methyldopa—Vomiting—Sorafenib—kidney cancer	0.000765	0.00111	CcSEcCtD
Methyldopa—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000764	0.00111	CcSEcCtD
Methyldopa—COMT—Neuronal System—ACHE—kidney cancer	0.000763	0.00435	CbGpPWpGaD
Methyldopa—Nervous system disorder—Paclitaxel—kidney cancer	0.000762	0.0011	CcSEcCtD
Methyldopa—Thrombocytopenia—Paclitaxel—kidney cancer	0.000761	0.0011	CcSEcCtD
Methyldopa—Rash—Sorafenib—kidney cancer	0.000758	0.0011	CcSEcCtD
Methyldopa—Dermatitis—Sorafenib—kidney cancer	0.000758	0.0011	CcSEcCtD
Methyldopa—Breast disorder—Doxorubicin—kidney cancer	0.000756	0.00109	CcSEcCtD
Methyldopa—Skin disorder—Paclitaxel—kidney cancer	0.000755	0.00109	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000753	0.00109	CcSEcCtD
Methyldopa—Headache—Sorafenib—kidney cancer	0.000753	0.00109	CcSEcCtD
Methyldopa—Diarrhoea—Dactinomycin—kidney cancer	0.00075	0.00108	CcSEcCtD
Methyldopa—Vomiting—Sunitinib—kidney cancer	0.000736	0.00106	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—HIF1A—kidney cancer	0.000734	0.00419	CbGpPWpGaD
Methyldopa—Body temperature increased—Gemcitabine—kidney cancer	0.000734	0.00106	CcSEcCtD
Methyldopa—ADRA2A—Integration of energy metabolism—ITPR2—kidney cancer	0.000732	0.00417	CbGpPWpGaD
Methyldopa—Rash—Sunitinib—kidney cancer	0.00073	0.00106	CcSEcCtD
Methyldopa—Dermatitis—Sunitinib—kidney cancer	0.000729	0.00105	CcSEcCtD
Methyldopa—Abdominal distension—Doxorubicin—kidney cancer	0.000728	0.00105	CcSEcCtD
Methyldopa—Headache—Sunitinib—kidney cancer	0.000725	0.00105	CcSEcCtD
Methyldopa—Hypersensitivity—Vincristine—kidney cancer	0.000721	0.00104	CcSEcCtD
Methyldopa—Eosinophilia—Doxorubicin—kidney cancer	0.000716	0.00104	CcSEcCtD
Methyldopa—COMT—Biological oxidations—GSTM1—kidney cancer	0.000715	0.00408	CbGpPWpGaD
Methyldopa—Nausea—Sorafenib—kidney cancer	0.000714	0.00103	CcSEcCtD
Methyldopa—Pancreatitis—Doxorubicin—kidney cancer	0.000709	0.00103	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000708	0.00102	CcSEcCtD
Methyldopa—ADRA2A—Regulation of insulin secretion—SLC2A1—kidney cancer	0.000705	0.00402	CbGpPWpGaD
Methyldopa—COMT—Metapathway biotransformation—GSTM1—kidney cancer	0.000705	0.00402	CbGpPWpGaD
Methyldopa—Angina pectoris—Doxorubicin—kidney cancer	0.000704	0.00102	CcSEcCtD
Methyldopa—Asthenia—Vincristine—kidney cancer	0.000702	0.00102	CcSEcCtD
Methyldopa—Leukopenia—Capecitabine—kidney cancer	0.0007	0.00101	CcSEcCtD
Methyldopa—Paraesthesia—Paclitaxel—kidney cancer	0.000698	0.00101	CcSEcCtD
Methyldopa—Vomiting—Dactinomycin—kidney cancer	0.000697	0.00101	CcSEcCtD
Methyldopa—Rash—Dactinomycin—kidney cancer	0.000691	0.000999	CcSEcCtD
Methyldopa—Nausea—Sunitinib—kidney cancer	0.000687	0.000994	CcSEcCtD
Methyldopa—Pancytopenia—Doxorubicin—kidney cancer	0.000687	0.000994	CcSEcCtD
Methyldopa—COMT—Biological oxidations—CYP1A1—kidney cancer	0.000678	0.00387	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ACY1—kidney cancer	0.000672	0.00383	CbGpPWpGaD
Methyldopa—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000671	0.000971	CcSEcCtD
Methyldopa—Diarrhoea—Vincristine—kidney cancer	0.00067	0.000969	CcSEcCtD
Methyldopa—COMT—Metapathway biotransformation—CYP1A1—kidney cancer	0.000669	0.00381	CbGpPWpGaD
Methyldopa—Asthenia—Gemcitabine—kidney cancer	0.000666	0.000964	CcSEcCtD
Methyldopa—Myalgia—Capecitabine—kidney cancer	0.000665	0.000963	CcSEcCtD
Methyldopa—Arthralgia—Capecitabine—kidney cancer	0.000665	0.000963	CcSEcCtD
Methyldopa—Constipation—Paclitaxel—kidney cancer	0.000665	0.000962	CcSEcCtD
Methyldopa—COMT—Neuronal System—BCHE—kidney cancer	0.000664	0.00379	CbGpPWpGaD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000661	0.000956	CcSEcCtD
Methyldopa—Weight increased—Doxorubicin—kidney cancer	0.000658	0.000952	CcSEcCtD
Methyldopa—Nausea—Dactinomycin—kidney cancer	0.000651	0.000941	CcSEcCtD
Methyldopa—Dizziness—Vincristine—kidney cancer	0.000647	0.000936	CcSEcCtD
Methyldopa—Infestation NOS—Doxorubicin—kidney cancer	0.000645	0.000933	CcSEcCtD
Methyldopa—Infestation—Doxorubicin—kidney cancer	0.000645	0.000933	CcSEcCtD
Methyldopa—Oedema—Capecitabine—kidney cancer	0.000638	0.000923	CcSEcCtD
Methyldopa—Diarrhoea—Gemcitabine—kidney cancer	0.000635	0.000919	CcSEcCtD
Methyldopa—Infection—Capecitabine—kidney cancer	0.000634	0.000917	CcSEcCtD
Methyldopa—Jaundice—Doxorubicin—kidney cancer	0.000628	0.000909	CcSEcCtD
Methyldopa—Nervous system disorder—Capecitabine—kidney cancer	0.000626	0.000905	CcSEcCtD
Methyldopa—Thrombocytopenia—Capecitabine—kidney cancer	0.000625	0.000904	CcSEcCtD
Methyldopa—Vomiting—Vincristine—kidney cancer	0.000622	0.0009	CcSEcCtD
Methyldopa—Skin disorder—Capecitabine—kidney cancer	0.00062	0.000897	CcSEcCtD
Methyldopa—Rash—Vincristine—kidney cancer	0.000617	0.000893	CcSEcCtD
Methyldopa—Dermatitis—Vincristine—kidney cancer	0.000617	0.000892	CcSEcCtD
Methyldopa—Body temperature increased—Paclitaxel—kidney cancer	0.000615	0.000889	CcSEcCtD
Methyldopa—Headache—Vincristine—kidney cancer	0.000613	0.000887	CcSEcCtD
Methyldopa—Hepatobiliary disease—Doxorubicin—kidney cancer	0.00061	0.000882	CcSEcCtD
Methyldopa—Agranulocytosis—Doxorubicin—kidney cancer	0.000602	0.000871	CcSEcCtD
Methyldopa—COMT—Metabolism—ACY1—kidney cancer	0.000596	0.0034	CbGpPWpGaD
Methyldopa—Vomiting—Gemcitabine—kidney cancer	0.00059	0.000854	CcSEcCtD
Methyldopa—Bradycardia—Doxorubicin—kidney cancer	0.000589	0.000853	CcSEcCtD
Methyldopa—Rash—Gemcitabine—kidney cancer	0.000585	0.000847	CcSEcCtD
Methyldopa—Dermatitis—Gemcitabine—kidney cancer	0.000585	0.000846	CcSEcCtD
Methyldopa—Headache—Gemcitabine—kidney cancer	0.000582	0.000842	CcSEcCtD
Methyldopa—Nausea—Vincristine—kidney cancer	0.000581	0.000841	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000581	0.000841	CcSEcCtD
Methyldopa—Hepatitis—Doxorubicin—kidney cancer	0.000579	0.000837	CcSEcCtD
Methyldopa—Paraesthesia—Capecitabine—kidney cancer	0.000573	0.000829	CcSEcCtD
Methyldopa—Hypersensitivity—Paclitaxel—kidney cancer	0.000573	0.000829	CcSEcCtD
Methyldopa—DDC—Metabolism—PDHB—kidney cancer	0.000571	0.00326	CbGpPWpGaD
Methyldopa—Connective tissue disorder—Doxorubicin—kidney cancer	0.000569	0.000823	CcSEcCtD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000564	0.00322	CbGpPWpGaD
Methyldopa—Asthenia—Paclitaxel—kidney cancer	0.000558	0.000807	CcSEcCtD
Methyldopa—ADRA2A—Integration of energy metabolism—SLC2A1—kidney cancer	0.000555	0.00316	CbGpPWpGaD
Methyldopa—Nausea—Gemcitabine—kidney cancer	0.000552	0.000798	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000551	0.000797	CcSEcCtD
Methyldopa—Constipation—Capecitabine—kidney cancer	0.000546	0.000789	CcSEcCtD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000545	0.00311	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000544	0.0031	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000544	0.0031	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000544	0.0031	CbGpPWpGaD
Methyldopa—Cardiac disorder—Doxorubicin—kidney cancer	0.000537	0.000777	CcSEcCtD
Methyldopa—DDC—Metabolism—CCBL1—kidney cancer	0.000537	0.00306	CbGpPWpGaD
Methyldopa—Diarrhoea—Paclitaxel—kidney cancer	0.000532	0.00077	CcSEcCtD
Methyldopa—Angiopathy—Doxorubicin—kidney cancer	0.000525	0.00076	CcSEcCtD
Methyldopa—Mediastinal disorder—Doxorubicin—kidney cancer	0.000522	0.000755	CcSEcCtD
Methyldopa—Dizziness—Paclitaxel—kidney cancer	0.000514	0.000744	CcSEcCtD
Methyldopa—COMT—Metabolism—PDHB—kidney cancer	0.000507	0.00289	CbGpPWpGaD
Methyldopa—Mental disorder—Doxorubicin—kidney cancer	0.000507	0.000734	CcSEcCtD
Methyldopa—COMT—Biological oxidations—POMC—kidney cancer	0.000506	0.00288	CbGpPWpGaD
Methyldopa—Body temperature increased—Capecitabine—kidney cancer	0.000504	0.00073	CcSEcCtD
Methyldopa—Flatulence—Doxorubicin—kidney cancer	0.000496	0.000718	CcSEcCtD
Methyldopa—Vomiting—Paclitaxel—kidney cancer	0.000494	0.000715	CcSEcCtD
Methyldopa—Rash—Paclitaxel—kidney cancer	0.00049	0.000709	CcSEcCtD
Methyldopa—Dermatitis—Paclitaxel—kidney cancer	0.00049	0.000709	CcSEcCtD
Methyldopa—Headache—Paclitaxel—kidney cancer	0.000487	0.000705	CcSEcCtD
Methyldopa—COMT—Metabolism—CCBL1—kidney cancer	0.000477	0.00272	CbGpPWpGaD
Methyldopa—Hypersensitivity—Capecitabine—kidney cancer	0.00047	0.00068	CcSEcCtD
Methyldopa—DDC—Metabolism—PPAT—kidney cancer	0.000466	0.00265	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GLIPR1—kidney cancer	0.000466	0.00265	CbGpPWpGaD
Methyldopa—Nausea—Paclitaxel—kidney cancer	0.000462	0.000668	CcSEcCtD
Methyldopa—Asthenia—Capecitabine—kidney cancer	0.000458	0.000662	CcSEcCtD
Methyldopa—Leukopenia—Doxorubicin—kidney cancer	0.000451	0.000653	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—JUN—kidney cancer	0.000443	0.00252	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—BRAF—kidney cancer	0.000442	0.00252	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—CTNNB1—kidney cancer	0.000439	0.0025	CbGpPWpGaD
Methyldopa—Diarrhoea—Capecitabine—kidney cancer	0.000436	0.000632	CcSEcCtD
Methyldopa—DDC—Metabolism—APRT—kidney cancer	0.000433	0.00247	CbGpPWpGaD
Methyldopa—DDC—Metabolism—FH—kidney cancer	0.000433	0.00247	CbGpPWpGaD
Methyldopa—Arthralgia—Doxorubicin—kidney cancer	0.000429	0.000621	CcSEcCtD
Methyldopa—Myalgia—Doxorubicin—kidney cancer	0.000429	0.000621	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000426	0.000616	CcSEcCtD
Methyldopa—Dizziness—Capecitabine—kidney cancer	0.000422	0.00061	CcSEcCtD
Methyldopa—COMT—Metabolism—PPAT—kidney cancer	0.000413	0.00236	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GLIPR1—kidney cancer	0.000413	0.00236	CbGpPWpGaD
Methyldopa—Oedema—Doxorubicin—kidney cancer	0.000411	0.000595	CcSEcCtD
Methyldopa—Infection—Doxorubicin—kidney cancer	0.000409	0.000591	CcSEcCtD
Methyldopa—DDC—Metabolism—GPC3—kidney cancer	0.000407	0.00232	CbGpPWpGaD
Methyldopa—Vomiting—Capecitabine—kidney cancer	0.000406	0.000587	CcSEcCtD
Methyldopa—ADRA2A—Hemostasis—L1CAM—kidney cancer	0.000405	0.00231	CbGpPWpGaD
Methyldopa—Nervous system disorder—Doxorubicin—kidney cancer	0.000403	0.000583	CcSEcCtD
Methyldopa—Thrombocytopenia—Doxorubicin—kidney cancer	0.000403	0.000583	CcSEcCtD
Methyldopa—Rash—Capecitabine—kidney cancer	0.000402	0.000582	CcSEcCtD
Methyldopa—Dermatitis—Capecitabine—kidney cancer	0.000402	0.000581	CcSEcCtD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—ITPR2—kidney cancer	0.0004	0.00228	CbGpPWpGaD
Methyldopa—Headache—Capecitabine—kidney cancer	0.0004	0.000578	CcSEcCtD
Methyldopa—Skin disorder—Doxorubicin—kidney cancer	0.000399	0.000578	CcSEcCtD
Methyldopa—DDC—Metabolism—CA2—kidney cancer	0.000396	0.00226	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—VEGFA—kidney cancer	0.000387	0.0022	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ALAD—kidney cancer	0.000386	0.0022	CbGpPWpGaD
Methyldopa—COMT—Metabolism—APRT—kidney cancer	0.000384	0.00219	CbGpPWpGaD
Methyldopa—COMT—Metabolism—FH—kidney cancer	0.000384	0.00219	CbGpPWpGaD
Methyldopa—Nausea—Capecitabine—kidney cancer	0.000379	0.000548	CcSEcCtD
Methyldopa—DDC—Metabolism—ST3GAL2—kidney cancer	0.000377	0.00215	CbGpPWpGaD
Methyldopa—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000375	0.000542	CcSEcCtD
Methyldopa—ADRA2A—GPCR downstream signaling—OR4C13—kidney cancer	0.000369	0.00211	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—RAF1—kidney cancer	0.000369	0.00211	CbGpPWpGaD
Methyldopa—Paraesthesia—Doxorubicin—kidney cancer	0.000369	0.000534	CcSEcCtD
Methyldopa—DDC—Metabolism—ALDH1A1—kidney cancer	0.000368	0.0021	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—JUN—kidney cancer	0.000361	0.00206	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GPC3—kidney cancer	0.000361	0.00206	CbGpPWpGaD
Methyldopa—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000355	0.000514	CcSEcCtD
Methyldopa—DDC—Metabolism—PGK1—kidney cancer	0.000353	0.00201	CbGpPWpGaD
Methyldopa—DDC—Metabolism—SLC5A3—kidney cancer	0.000353	0.00201	CbGpPWpGaD
Methyldopa—Constipation—Doxorubicin—kidney cancer	0.000352	0.000509	CcSEcCtD
Methyldopa—COMT—Metabolism—CA2—kidney cancer	0.000352	0.002	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—PTEN—kidney cancer	0.00035	0.00199	CbGpPWpGaD
Methyldopa—DDC—Metabolism—LDHB—kidney cancer	0.000346	0.00197	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALAD—kidney cancer	0.000343	0.00195	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—BRAF—kidney cancer	0.000339	0.00193	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—OR4C13—kidney cancer	0.000336	0.00191	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ST3GAL2—kidney cancer	0.000334	0.00191	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALDH1A1—kidney cancer	0.000327	0.00186	CbGpPWpGaD
Methyldopa—Body temperature increased—Doxorubicin—kidney cancer	0.000325	0.00047	CcSEcCtD
Methyldopa—ADRA2A—G alpha (i) signalling events—ANXA1—kidney cancer	0.00032	0.00182	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PGK1—kidney cancer	0.000313	0.00179	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SLC5A3—kidney cancer	0.000313	0.00179	CbGpPWpGaD
Methyldopa—COMT—Metabolism—LDHB—kidney cancer	0.000307	0.00175	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ANXA2—kidney cancer	0.000307	0.00175	CbGpPWpGaD
Methyldopa—Hypersensitivity—Doxorubicin—kidney cancer	0.000303	0.000438	CcSEcCtD
Methyldopa—DDC—Metabolism—CA9—kidney cancer	0.0003	0.00171	CbGpPWpGaD
Methyldopa—Asthenia—Doxorubicin—kidney cancer	0.000295	0.000427	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000287	0.00163	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—RAF1—kidney cancer	0.000283	0.00161	CbGpPWpGaD
Methyldopa—Diarrhoea—Doxorubicin—kidney cancer	0.000281	0.000407	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000277	0.00158	CbGpPWpGaD
Methyldopa—Dizziness—Doxorubicin—kidney cancer	0.000272	0.000393	CcSEcCtD
Methyldopa—COMT—Metabolism—CA9—kidney cancer	0.000266	0.00152	CbGpPWpGaD
Methyldopa—Vomiting—Doxorubicin—kidney cancer	0.000261	0.000378	CcSEcCtD
Methyldopa—Rash—Doxorubicin—kidney cancer	0.000259	0.000375	CcSEcCtD
Methyldopa—Dermatitis—Doxorubicin—kidney cancer	0.000259	0.000375	CcSEcCtD
Methyldopa—Headache—Doxorubicin—kidney cancer	0.000258	0.000373	CcSEcCtD
Methyldopa—DDC—Metabolism—CRABP1—kidney cancer	0.000255	0.00145	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—KCNMA1—kidney cancer	0.000254	0.00145	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ANXA1—kidney cancer	0.000254	0.00145	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—MAPK1—kidney cancer	0.000253	0.00144	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—IGF2—kidney cancer	0.000246	0.0014	CbGpPWpGaD
Methyldopa—Nausea—Doxorubicin—kidney cancer	0.000244	0.000353	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—TP53—kidney cancer	0.000239	0.00136	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ITPR2—kidney cancer	0.000237	0.00135	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ACY1—kidney cancer	0.000237	0.00135	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CRABP1—kidney cancer	0.000227	0.00129	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—GRB7—kidney cancer	0.000222	0.00127	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ABCB1—kidney cancer	0.000219	0.00125	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ACHE—kidney cancer	0.000216	0.00123	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTT1—kidney cancer	0.000216	0.00123	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ITPR2—kidney cancer	0.000211	0.0012	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ITPR2—kidney cancer	0.000206	0.00118	CbGpPWpGaD
Methyldopa—DDC—Metabolism—SCARB1—kidney cancer	0.000205	0.00117	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS1—kidney cancer	0.000203	0.00116	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PDHB—kidney cancer	0.000202	0.00115	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PSMD7—kidney cancer	0.000199	0.00113	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—OR4C13—kidney cancer	0.000198	0.00113	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—MAPK1—kidney cancer	0.000194	0.00111	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—ANXA1—kidney cancer	0.000193	0.0011	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ACHE—kidney cancer	0.000192	0.00109	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTT1—kidney cancer	0.000192	0.00109	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CCBL1—kidney cancer	0.00019	0.00108	CbGpPWpGaD
Methyldopa—DDC—Metabolism—BCHE—kidney cancer	0.000188	0.00107	CbGpPWpGaD
Methyldopa—DDC—Metabolism—SLC5A5—kidney cancer	0.000186	0.00106	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SCARB1—kidney cancer	0.000182	0.00104	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS1—kidney cancer	0.00018	0.00103	CbGpPWpGaD
Methyldopa—DDC—Metabolism—SLC2A1—kidney cancer	0.00018	0.00102	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PSMD7—kidney cancer	0.000176	0.00101	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LATS1—kidney cancer	0.000169	0.000961	CbGpPWpGaD
Methyldopa—COMT—Metabolism—BCHE—kidney cancer	0.000167	0.000954	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SLC5A5—kidney cancer	0.000165	0.000942	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPAT—kidney cancer	0.000164	0.000937	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GLIPR1—kidney cancer	0.000164	0.000937	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SLC2A1—kidney cancer	0.00016	0.00091	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—POMC—kidney cancer	0.000157	0.000892	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKAP13—kidney cancer	0.000153	0.000875	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—FH—kidney cancer	0.000153	0.000871	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APRT—kidney cancer	0.000153	0.000871	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IFNA1—kidney cancer	0.000152	0.000864	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTP1—kidney cancer	0.00015	0.000855	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GPC3—kidney cancer	0.000144	0.000819	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AMER1—kidney cancer	0.000143	0.000817	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ABCB1—kidney cancer	0.000142	0.000809	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IFNA2—kidney cancer	0.000141	0.000804	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CA2—kidney cancer	0.00014	0.000796	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKAP13—kidney cancer	0.000139	0.000794	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTM1—kidney cancer	0.000138	0.000785	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALAD—kidney cancer	0.000136	0.000776	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—RAF1—kidney cancer	0.000136	0.000773	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTP1—kidney cancer	0.000133	0.000759	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ST3GAL2—kidney cancer	0.000133	0.000758	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYP1A1—kidney cancer	0.000131	0.000744	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—ITPR2—kidney cancer	0.00013	0.000744	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALDH1A1—kidney cancer	0.00013	0.00074	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IGF2—kidney cancer	0.000127	0.000724	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ABCB1—kidney cancer	0.000126	0.000718	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC5A3—kidney cancer	0.000125	0.00071	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PGK1—kidney cancer	0.000125	0.00071	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	0.000124	0.000709	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—RAF1—kidney cancer	0.000124	0.000705	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTM1—kidney cancer	0.000122	0.000697	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LDHB—kidney cancer	0.000122	0.000696	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—IL2—kidney cancer	0.000122	0.000693	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GPC3—kidney cancer	0.00012	0.000685	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CER1—kidney cancer	0.00012	0.000685	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ITPR2—kidney cancer	0.000118	0.000675	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP1A1—kidney cancer	0.000116	0.000661	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—ANXA1—kidney cancer	0.000109	0.000623	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CA9—kidney cancer	0.000106	0.000604	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—kidney cancer	0.000103	0.000589	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SFRP2—kidney cancer	0.000102	0.000582	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ANXA1—kidney cancer	9.93e-05	0.000566	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—MAPK3—kidney cancer	9.77e-05	0.000557	CbGpPWpGaD
Methyldopa—DDC—Metabolism—POMC—kidney cancer	9.74e-05	0.000555	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—POMC—kidney cancer	9.48e-05	0.00054	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—MAPK1—kidney cancer	9.3e-05	0.00053	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CRABP1—kidney cancer	9e-05	0.000513	CbGpPWpGaD
Methyldopa—COMT—Metabolism—POMC—kidney cancer	8.65e-05	0.000493	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ITPR2—kidney cancer	8.37e-05	0.000477	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKAP13—kidney cancer	8.23e-05	0.000469	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASP2—kidney cancer	8.23e-05	0.000469	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	8.07e-05	0.00046	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—kidney cancer	7.77e-05	0.000443	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTT1—kidney cancer	7.63e-05	0.000435	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ACHE—kidney cancer	7.63e-05	0.000435	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GRB7—kidney cancer	7.53e-05	0.000429	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SCARB1—kidney cancer	7.22e-05	0.000412	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS1—kidney cancer	7.15e-05	0.000408	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PSMD7—kidney cancer	7.01e-05	0.0004	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ITPR2—kidney cancer	7e-05	0.000399	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—RAF1—kidney cancer	6.99e-05	0.000398	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—kidney cancer	6.9e-05	0.000393	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTEN—kidney cancer	6.77e-05	0.000386	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—BCHE—kidney cancer	6.65e-05	0.000379	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC5A5—kidney cancer	6.57e-05	0.000374	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CTNNA1—kidney cancer	6.34e-05	0.000362	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC2A1—kidney cancer	6.34e-05	0.000362	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HSPB1—kidney cancer	6.31e-05	0.00036	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EIF4EBP1—kidney cancer	6.31e-05	0.00036	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IL2—kidney cancer	6.27e-05	0.000357	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTEN—kidney cancer	6.01e-05	0.000343	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PSMD7—kidney cancer	5.86e-05	0.000334	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ANXA1—kidney cancer	5.86e-05	0.000334	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TSC1—kidney cancer	5.86e-05	0.000334	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FLT1—kidney cancer	5.68e-05	0.000324	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—POMC—kidney cancer	5.36e-05	0.000305	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—kidney cancer	5.32e-05	0.000304	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTP1—kidney cancer	5.29e-05	0.000302	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JUNB—kidney cancer	5.26e-05	0.0003	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PAK1—kidney cancer	5.26e-05	0.0003	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MAPK3—kidney cancer	5.04e-05	0.000287	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCB1—kidney cancer	5.01e-05	0.000285	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—POMC—kidney cancer	4.86e-05	0.000277	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTM1—kidney cancer	4.86e-05	0.000277	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MAPK1—kidney cancer	4.79e-05	0.000273	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CA—kidney cancer	4.78e-05	0.000272	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP1A1—kidney cancer	4.61e-05	0.000263	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—KRAS—kidney cancer	4.53e-05	0.000258	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF2—kidney cancer	4.3e-05	0.000245	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN2B—kidney cancer	4.29e-05	0.000244	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CA—kidney cancer	4.24e-05	0.000242	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF1R—kidney cancer	4.16e-05	0.000237	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CA—kidney cancer	4.16e-05	0.000237	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—kidney cancer	4.02e-05	0.000229	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—RAF1—kidney cancer	4.01e-05	0.000229	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—IL2—kidney cancer	3.96e-05	0.000226	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL2—kidney cancer	3.6e-05	0.000205	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—POMC—kidney cancer	3.44e-05	0.000196	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HIF1A—kidney cancer	3.43e-05	0.000195	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TSC2—kidney cancer	3.42e-05	0.000195	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KDR—kidney cancer	3.28e-05	0.000187	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KIT—kidney cancer	3.02e-05	0.000172	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APC—kidney cancer	3.02e-05	0.000172	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAPK3—kidney cancer	2.89e-05	0.000165	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—POMC—kidney cancer	2.87e-05	0.000164	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BRAF—kidney cancer	2.84e-05	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	2.75e-05	0.000157	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—kidney cancer	2.74e-05	0.000156	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	2.63e-05	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	2.6e-05	0.000148	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTEN—kidney cancer	2.39e-05	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	2.39e-05	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RAF1—kidney cancer	2.37e-05	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RELA—kidney cancer	2.36e-05	0.000134	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	2.34e-05	0.000134	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MTOR—kidney cancer	2.31e-05	0.000132	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	2.17e-05	0.000124	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL2—kidney cancer	2.12e-05	0.000121	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCND1—kidney cancer	2.07e-05	0.000118	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JUN—kidney cancer	2.07e-05	0.000118	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	2.05e-05	0.000117	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTEN—kidney cancer	2e-05	0.000114	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	1.81e-05	0.000103	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	1.71e-05	9.73e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CA—kidney cancer	1.69e-05	9.61e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—kidney cancer	1.66e-05	9.47e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	1.62e-05	9.26e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KRAS—kidney cancer	1.53e-05	8.75e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	1.41e-05	8.04e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—kidney cancer	1.36e-05	7.78e-05	CbGpPWpGaD
